February 9, 2016

Novocure’s Phase 3 Pivotal Trial Results in Newly Diagnosed Glioblastoma Selected For ASCO’s Clinical Cancer Advances 2016 Report

February 09, 2016 11:21 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure’s (NASDAQ: NVCR) phase 3 pivotal clinical trial results of Tumor Treating Fields (TTFields) in combination with temozolomide in newly diagnosed glioblastoma (GBM) have been selected for inclusion in… Read More
learn more
February 9, 2016

Novocure’s Phase 3 Pivotal Trial Results in Newly Diagnosed Glioblastoma Selected For ASCO’s Clinical Cancer Advances 2016 Report

February 09, 2016 11:21 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure’s (NASDAQ: NVCR) phase 3 pivotal clinical trial results of Tumor Treating Fields (TTFields) in combination with temozolomide in newly diagnosed glioblastoma (GBM) have been selected for inclusion in… Read More
learn more
February 1, 2016

Novocure to Report Fourth Quarter, Year-End Financial Results

February 01, 2016 04:35 PM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will hold a conference call and webcast to discuss its fourth quarter and full-year 2015 financial results at 5 p.m. EST on Feb. 29, 2016. Read More
learn more
February 1, 2016

Novocure to Report Fourth Quarter, Year-End Financial Results

February 01, 2016 04:35 PM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will hold a conference call and webcast to discuss its fourth quarter and full-year 2015 financial results at 5 p.m. EST on Feb. 29, 2016. Read More
learn more
February 1, 2016

Novocure to Report Fourth Quarter, Year-End Financial Results

February 01, 2016 04:35 PM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will hold a conference call and webcast to discuss its fourth quarter and full-year 2015 financial results at 5 p.m. EST on Feb. 29, 2016. Read More
learn more